Scarica l'app Stockscreener
3.27
0.31%
0.01
Dopo l'orario di chiusura:
3.30
0.03
+0.92%
Precedente Chiudi:
$3.26
Aprire:
$3.32
Volume 24 ore:
7,244
Relative Volume:
0.15
Capitalizzazione di mercato:
$17.50M
Reddito:
-
Utile/perdita netta:
$-16.35M
Rapporto P/E:
-1.0721
EPS:
-3.05
Flusso di cassa netto:
$-11.88M
1 W Prestazione:
+3.15%
1M Prestazione:
+4.14%
6M Prestazione:
-27.97%
1 anno Prestazione:
-48.99%
Intervallo 1D:
$3.27
$3.32
Intervallo di 1 settimana:
$3.10
$3.32
Portata 52W:
$2.6838
$6.50
Lipocine Inc Stock (LPCN) Company Profile
Nome
Lipocine Inc
Settore
Industria
Telefono
801 994 7383
Indirizzo
675 ARAPEEN DRIVE, SUITE 202, SALT LAKE CITY, UT
Confronta LPCN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LPCN
Lipocine Inc
|
3.27 | 17.44M | 0 | -16.35M | -11.88M | -3.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
476.95 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.39 | 60.56B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.64 | 42.41B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
575.42 | 34.96B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.83 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Lipocine Inc Stock (LPCN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-06-24 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-12-10 | Aggiornamento | Ladenburg Thalmann | Neutral → Buy |
| 2018-01-12 | Reiterato | H.C. Wainwright | Buy |
| 2018-01-11 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2017-12-08 | Ripresa | H.C. Wainwright | Buy |
| 2016-10-07 | Iniziato | H.C. Wainwright | Buy |
| 2015-07-22 | Iniziato | ROTH Capital | Buy |
| 2015-06-23 | Iniziato | Canaccord Genuity | Buy |
Mostra tutto
Lipocine Inc Borsa (LPCN) Ultime notizie
Is Lipocine Inc. a good long term investmentFree Wealth Planning Blueprint - Autocar Professional
What analysts say about Lipocine Inc. stockFree Daily Trading Room Entry - jammulinksnews.com
What drives Lipocine Inc. stock priceBreakthrough stock performance - jammulinksnews.com
Lipocine Inc. Stock Analysis and ForecastSpectacular growth rates - jammulinksnews.com
What makes Lipocine Inc. stock price move sharplyTrade With Low Risk Exposure - beatles.ru
How Lipocine Inc. stock performs during market volatilitySmall Risk Large Return Trades - Newser
Why Lipocine Inc. stock attracts strong analyst attentionStable Growth Stock Picks - Newser
Lipocine stock maintains Buy rating at H.C. Wainwright on PPD treatment potential - Investing.com Australia
Lipocine stock maintains Buy rating at H.C. Wainwright as Phase 3 trial begins - Investing.com
First Patient Receives Lipocene's LPCN 1154 for Postpartum Depression in Phase 3 Clinical Trial - Patient Care Online
LPCN Begins Pivotal Phase 3 Trial for Postpartum Depression Treatment | LPCN Stock News - GuruFocus
Lipocine Begins Phase 3 Trial for LPCN 1154 - TipRanks
Lipocine to Host R&D Event on July 9 - TipRanks
Lipocine to Host Virtual R&D Investor Event to Discuss LPCN 1154 (BRLIZIO™) as a Treatment for Postpartum Depression on July 9, 2025 - Yahoo Finance
HC Wainwright Estimates Lipocine’s Q1 Earnings (NASDAQ:LPCN) - Defense World
Lipocine (NASDAQ:LPCN) Given Buy Rating at HC Wainwright - Defense World
LPCN Stock Maintains 'Buy' Rating with $8.00 Price Target | LPCN Stock News - GuruFocus
Lipocine partner files for Canadian approval of oral TRT drug By Investing.com - Investing.com South Africa
Verity Pharma Files TLANDO Drug Submission In Canada For Lipocine - Nasdaq
LPCN: Lipocine's TRT Submission in Canada Marks Key Milestone | - GuruFocus
Lipocine Announces Filing Of New Drug Submission For TLANDO In Canada - MarketScreener
Lipocine Announces Filing of New Drug Submission for TLANDO® in Canada - PR Newswire
Lipocine’s Partner Files New Drug Submission in Canada - TipRanks
Lipocine Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits - Quantisnow
Groundbreaking Oral Testosterone Treatment Eyes 700,000-Strong Canadian Market After FDA Success - Stock Titan
Lipocine Inc. (NASDAQ:LPCN) Short Interest Update - Defense World
Lipocine Approves Key Proposals at Shareholder Meeting - TipRanks
Lipocine Inc Azioni (LPCN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
4.91%
0.25%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):